纳米刀联合DEB-TACE治疗高危部位肝细胞癌1例并文献复习
A Case Report and Literature Review of Nanoknife Combined with DEB-TACE in the Treatment of High-Risk Site Hepatocellular Carcinoma
DOI: 10.12677/ACM.2023.1371675, PDF,   
作者: 赵 猛：青岛大学医学部，山东 青岛；张 伟, 张 浩：青岛大学附属医院介入医学中心，山东 青岛；王振光*：青岛大学附属医院核医学科，山东 青岛
关键词: 纳米刀；载药微球；经导管肝动脉化疗栓塞；肝细胞癌；Nanoknife； Drug-Eluting Beads； Transcathete Arterial Chemoembolization； Hepatocellular Carcino-ma
摘要: 肝癌起病隐匿，80%左右的患者确诊时已失去手术机会。而TACE、RFA和MWA等治疗方式因微创和临床疗效确切等优势，已经成为肝癌治疗的重要选择。然而由于热沉效应及高温对消融范围内组织的破坏无选择性，限制了热消融在临近大血管、胆管和重要器官等高危部位的肝癌治疗中的应用。本例患者经纳米刀联合DEB-TACE治疗后，短期内肿瘤控制效果良好，临近血管保存完好，提示针对高危部位肝癌，纳米刀联合DEB-TACE的综合治疗模式可能是有效和安全的新治疗方案，为高危部位肝癌治疗提供新的方向。
Abstract: The onset of liver cancer is hidden, and about 80% of patients have lost the opportunity for surgery when diagnosed. TACE, RFA, and MWA have become important choices for the treatment of liver cancer due to their precise clinical efficacy and minimally invasive advantages. However, due to the heat sink effect and the non selective destruction of the tissue within the ablation range by high temperature, the application of thermal ablation in the treatment of liver cancer near high-risk ar-eas such as Great vessels, bile ducts and important organs is limited. After the combination of nanoknife and DEB-TACE treatment, the tumor control effect of this patient was good in the short term, and the adjacent blood vessels are well preserved, indicating that the comprehensive treat-ment of nanoknife and DEB-TACE may be an effective new treatment plan for high-risk liver cancer, providing new ideas for the treatment of high-risk liver cancer.
文章引用：赵猛, 张伟, 张浩, 王振光. 纳米刀联合DEB-TACE治疗高危部位肝细胞癌1例并文献复习[J]. 临床医学进展, 2023, 13(7): 11964-11969. https://doi.org/10.12677/ACM.2023.1371675

参考文献

[1] Zhang, S., Sun, K., Zheng, R., et al. (2020) Cancer Incidence and Mortality in China, 2015. Journal of the National Cancer Center, 1, 2-11. [Google Scholar] [CrossRef] [PubMed]
[2] Zeng, H., Chen, W., Zheng, R., et al. (2018) Changing Cancer Survival in China during 2003-15: A Pooled Analysis of 17 Population-Based Cancer Registries. The Lancet Global Health, 6, E555-E567. [Google Scholar] [CrossRef] 
[3] Yang, J.D. and Heimbach, J.K. (2020) New Advances in the Diagnosis and Management of Hepatocellular Carcinoma. BMJ, 371, m3544. [Google Scholar] [CrossRef] [PubMed]
[4] Arellano, R.S. (2020) What’s New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Current Oncology Reports, 22, Article No. 105. [Google Scholar] [CrossRef] [PubMed]
[5] 戴子浩, 廖俊彬, 林满霞, 等. 纳米刀治疗原发性肝癌研究进展[J]. 中华肝脏外科手术学电子杂志, 2019, 8(2): 91-95.
[6] Lee, E.W., Chen, C., Prieto, V.E., et al. (2010) Ad-vanced Hepatic Ablation Technique for Creating Complete Cell Death: Irreversible Electroporation. Radiology, 255, 426-433. [Google Scholar] [CrossRef] [PubMed]
[7] 黄凯文. 履险如夷之纳米刀肝癌消融[J]. 肝癌电子杂志, 2015, 2(2): 36-41.
[8] Sutter, O., Calvo, J., N’kontchou, G., et al. (2017) Safety and Efficacy of Irreversible Electro-poration for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology, 284, 877-886. [Google Scholar] [CrossRef] [PubMed]
[9] Distelmaier, M., Barabasch, A., Heil, P., et al. (2017) Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins. Radiology, 285, 1023-1031. [Google Scholar] [CrossRef] [PubMed]
[10] 武中林, 谷铁树, 康一鹤, 等. 精准TACE在原发性肝癌中的应用[J]. 实用放射学杂志, 2016, 32(6): 933-937.
[11] 赵倩, 颜志平. 载药微球经导管动脉化疗栓塞治疗肝癌研究进展[J]. 介入放射学杂志, 2017, 26(11): 1052-1056.
[12] Onik, G. and Rubinsky, B. (2010) Irreversible Electro-poration: First Patient Experience Focal Therapy of Prostate Cancer. In: Rubinsky, B., Ed., Irreversible Electroporation, Springer, Berlin, 235-247. [Google Scholar] [CrossRef] 
[13] 陆健, 黄蔚, 王忠敏, 等. 影像引导经皮不可逆电穿孔消融治疗肾细胞癌4例[J]. 介入放射学杂志, 2018, 27(5): 443-446.
[14] Bhutiani, N., Philips, P., Scoggins, C.R., et al. (2016) Evaluation of Tolerability and Efficacy of Irreversible Electroporation (IRE) in Treatment of Child-Pugh B (7/8) Hepatocellular Carcinoma (HCC). HPB, 18, 593-599. [Google Scholar] [CrossRef] [PubMed]
[15] 李红, 尹芳, 罗贯虹, 等. CalliSpheres载药脂微球联合TACE与传统TACE治疗肝癌疗效对比分析[J]. 胃肠病学和肝病学杂志, 2019, 28(2): 171-174.
[16] Wu, B., Zhou, J., Ling, G.H., Zhu, D.Y. and Long, Q.Y. (2018) CalliSpheres Drug-Eluting Beads versus Lipiodol Transarterial Chemoemboli-zation in the Treatment of Hepatocellular Carcinoma: A Short-Term Efficacy and Safety Study. World Journal of Surgical Oncology, 16, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[17] 刘树鹏, 徐炯源, 冷尹, 等. 不可逆电穿孔消融联合化疗治疗肝胆管细胞癌1例[J]. 介入放射学杂志, 2019, 28(6): 530-532.
[18] Davalos, R.V., Mir, I.L. and Rubinsky, B. (2005) Tissue Ablation with Irreversible Electroporation. Annals of Biomedical Engineering, 33, 223-231. [Google Scholar] [CrossRef] [PubMed]
[19] Bhutiani, N., Agle, S., Li, Y., et al. (2016) Irreversi-ble Electroporation Enhances Delivery of Gemcitabine to Pancreatic Adenocarcinoma. Journal of Surgical Oncology, 114, 181-186. [Google Scholar] [CrossRef] [PubMed]
[20] Peter, I., Philip, R., Hong-Sik, Na., et al. (2019) Does Drug-Eluting Bead TACE Enhance the Local Effect of IRE? Imaging and Histopathological Evaluation in a Porcine Model. CardioVascular and Interventional Radiology, 42, 880-885. [Google Scholar] [CrossRef] [PubMed]

为你推荐